Abstract

Purpose This updated meta-analysis aimed to assess the diagnostic performance of circulating cell-free DNA (cf-DNA) for prostate cancer (PCa). Methods A systematic search was conducted in PubMed, Scopus, Web of Science, and Embase databases to retrieve related studies. Several diagnostic estimates, including sensitivity (SE), specificity (SP), likelihood ratios (LRs), and diagnostic odds ratio (DOR) were also used to perform the meta-synthesis. Additionally, the area under hierarchical summary receiver operating characteristic curves (AU-HSROC) was used as a global measure of test accuracy. Results Twenty-nine unique articles were enrolled in the meta-analysis. Pooled SE and SP for overall accuracy of cf-DNA in PCa were obtained as 0.54 (95 CI: 0.47-0.61) and 0.92 (95 CI: 0.88-0.95), respectively. Positive LR (PLR) was 6.8 (95 CI: 4.9-9.5, I-2: 92.98) and negative LR (NLR) was 0.5 (95 CI: 0.43-0.58). Pooled DOR was 13.56 (95 CI: 9.49-19.37) and the AU-HSROC was 0.83 (95 CI: 0.79-0.86). Conclusion The present study suggested that cf-DNA assays have comparable SE as well as remarkably higher SP (qualitative assays) than common biomarkers in the detection of PCa like prostate-specific antigen (PSA). In addition, cf-DNA assays have better performance in PCa confirmation and almost similar performance to PSA in excluding PCa patients.